Zevra Therapeutics
ZVRA
40 hedge funds and large institutions have $24.8M invested in Zevra Therapeutics in 2016 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 9 reducing their positions, and 23 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 9
31% less funds holding
Funds holding: 58 → 40 (-18)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
77% less capital invested
Capital invested by funds: $107M → $24.8M (-$81.9M)
78% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$4.09M |
| 2 |
SIM
Spark Investment Management
New York
|
+$959K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$669K |
| 4 |
DA
DSC Advisors
Chicago,
Illinois
|
+$513K |
| 5 |
Millennium Management
New York
|
+$377K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
-$5.14M |
| 2 |
BC
Broadfin Capital
New York
|
-$4.35M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.67M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$2.46M |
| 5 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
-$2.23M |
ZVRA Hedge Fund Activity: Q2 2016 in Review
40 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q2 2016, worth a combined $24.8M — down 77% from $107M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ZVRA and 5 opened new positions — a net loss of 18 holders — while 9 trimmed existing stakes and 18 added.
The largest buyer was Alyeska Investment Group, adding an estimated $4.09M. The largest seller was Schroder Investment Management Group, exiting entirely with an estimated $5.14M sold.
- 40 institutional investors held Zevra Therapeutics (ZVRA) as of Q2 2016, down from 58 in Q1 2016.
- Funds reported $24.8M of Zevra Therapeutics stock for Q2 2016, down 77% quarter-over-quarter.
- 5 funds opened new Zevra Therapeutics positions in Q2 2016 and 23 closed out, a net change of -18 holders.
- The largest Zevra Therapeutics buyer in Q2 2016 was Alyeska Investment Group, an estimated $4.09M added.
- The largest Zevra Therapeutics seller in Q2 2016 was Schroder Investment Management Group, an estimated $5.14M sold.
Based on aggregated 13F filings for Q2 2016.